Cargando…

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Detalles Bibliográficos
Autores principales:	Kutsch, Nadine, Pallasch, Christian, Tausch, Eugen, Böhme, Volkmar, Ritgen, Matthias, Liersch, Rüdiger, Wacker, Alexander, Jacobs, Georg, Trappe, Ralf Ulrich, Dreger, Peter, Fischer, Kirsten, Fink, Anna-Maria, Stilgenbauer, Stephan, Zhai, Shuyan, Li, Biao, Jürgensmeier, Juliane M., Rajakumaraswamy, Nishanthan, Bhargava, Pankaj, Hallek, Michael, Eichhorst, Barbara F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906452/ https://www.ncbi.nlm.nih.gov/pubmed/35284802 http://dx.doi.org/10.1097/HS9.0000000000000692

Ejemplares similares

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2020)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
por: Kittai, Adam S., et al.
Publicado: (2021)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
por: Al-Sawaf, Othman, et al.
Publicado: (2021)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement
por: Yu, Helen, et al.
Publicado: (2018)

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
por: Stilgenbauer, Stephan, et al.
Publicado: (2018)

Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib
por: Sender, Sina, et al.
Publicado: (2021)

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
por: Al-Sawaf, Othman, et al.
Publicado: (2017)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA
por: Meng, Amy, et al.
Publicado: (2021)

Bing-Neel Syndrome Successfully Treated with Tirabrutinib
por: Oyama, Takashi, et al.
Publicado: (2022)

Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib
por: Sharman, Jeff, et al.
Publicado: (2016)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia
por: Sekiguchi, Naohiro, et al.
Publicado: (2022)

Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia
por: Loftus, Joseph P., et al.
Publicado: (2020)

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
por: Freeman, C L, et al.
Publicado: (2016)

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
por: Bosch, Francesc, et al.
Publicado: (2019)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib
por: Yasuda, Hajime, et al.
Publicado: (2022)

The Impact of Tirabrutinib Monotherapy for Bing-Neel Syndrome in Waldenström's Macroglobulinemia
por: Sekiguchi, Naohiro
Publicado: (2022)

BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib
por: Jackson, Ross A., et al.
Publicado: (2023)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis
por: Schilhabel, Anke, et al.
Publicado: (2022)

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
por: Lin, David Y., et al.
Publicado: (2023)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

ML-17 Clinical usefulness of Tirabrutinib in recurrent PCNSL: single institute experience
por: Matsuura, Jin, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers
por: Ramanathan, Srini, et al.
Publicado: (2016)

Disseminated Enteroviral Infection Associated with Obinutuzumab
por: Dendle, Claire, et al.
Publicado: (2015)

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
por: Jaramillo, Sonia, et al.
Publicado: (2019)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
por: Fürstenau, Moritz, et al.
Publicado: (2019)

72/m mit Zufallsbefund einer Lymphozytose: Vorbereitung auf die Facharztprüfung: Fall 34
por: Langerbeins, Petra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eqrh14n904n95sdsui9bf74oqr